The development of a MEAI-based alcohol substitute by Clearmind Medicine directly targets a significant and growing market segment. As the no- and low-alcohol beverage market continues to expand, driven by increasing consumer health consciousness, Clearmind's program could meet a substantial market demand. This advancement could lead to increased investor interest and potentially higher stock prices in the short term, assuming successful development and market acceptance.